Best biotech stocks to buy in 2022

Biotechnology is a crucial part of our modern lives. This page picks out some of the leading companies in the biotechnology industry and explains what makes them stand out from the competition.
By:  &  Jayson Derrick
Updated: Sep 23, 2022
Tip: our preferred broker is, eToro: visit & create account

Our financial analysts have picked out the top five biotech companies that are at the top of their field. Additionally, you can find an explanation of the industry as a whole, along with the best place to find these biotech stocks.

What are the top biotech stocks to buy?

The table below contains the five companies our experts have chosen. You can either find up-to-date share price data through the table or scroll down to find out more information about each.

#Stock symbolCompany nameTrade now
1RGENRegeneron Pharmaceuticals Inc.
2NVAXNovavax, Inc.
3GILDGilead Sciences
4OCGNOcugen Inc.
5NBIXNeurocrine Biosciences, Inc.
List selected by our team of analysts, updated 27 January 2022.

For more information about each company, simply scroll down for more details such as market caps, revenue and product ranges.

1. Regeneron Pharmaceuticals Inc. (NASDAQ: RGEN)

Headquartered in New York and part of both the NASDAQ 100 and S&P 500 indexes, Regeneron Pharmaceuticals is a biotech and pharmaceutical company that was founded in 1988. Regeneron generates around $8 billion of revenue per year and employs over 8,000 staff.

Its top pharmaceutical products include Aflibercept, Analyst, Praluent, Dupixent, Kevzara, Libtayo, and Inmazeb, and they are used to treat things like inflammation, blindness, arthritis, cardiovascular disease, cancer and even Ebola. With a market cap of over $50 billion, its sheer scale and the variety of treatments it offers have secured its place on our list. 

Recently, Regeneron was in the news for providing an experimental COVID-19 antibody treatment for President Trump. Its recent share price performance has been solid if a little volatile, though we can foresee growth with the introduction of new treatments.

2. Novavax, Inc. (NASDAQ: NVAX)

Based in Maryland, US, and founded in 1987, Novavax is a pharmaceutical company that creates experimental vaccines for major diseases. It did not have a successful launch until its 2021 NVX-CoV2373 COVID-19 vaccine, and it has now applied for emergency use in the US. It also has a phase 3 clinical trial underway for an influenza vaccine, NanoFlu. 

Given its lack of a successful launch until 2021, its share price has been extremely volatile. However, from 2020 onwards, it has experienced rapid growth and has now has a market cap in excess of $12 billion. This makes it a strong growth stock that has the potential to generate dramatic returns, though its experimental focus comes with increased risks. 

Looking to the future, a major potential catalyst comes in the form of Novavax’s COVID-19 vaccine receiving formal authorisation. Moreover, Novavax claims its vaccine has higher efficacy than some of the major COVID-19 vaccines, though this is largely down to where and how it is tested. If the company can secure approval, it could be en route to profits. 

3. Gilead Sciences (NASDAQ: GILD)

Gilead Sciences is an American company that develops treatments for a variety of life threatening diseases. It’s best known for its treatment for Hepatitis B and C, HIV, and Influenza. Like many of the companies on this list, it was created in the 1980s, and has been public since 1992.

This type of stock often ebbs and flows with the success of its treatments and Gilead is no different. It did well initially out of the pandemic, thanks to a coronavirus treatment called Veklury, that sent its stock soaring above $80 and to its highest price in five years. As other companies developed vaccines, that price began to wane again.

The big thing with any biotech company is its ability to develop new drugs. Successful ones almost guarantee profits for many years but they are difficult to find and so one route is to buy up other companies to grow into new areas. Gilead has done this to get exposure to cancer and cardiovascular medication, so that it has a robust range of treatments for serious illnesses that it can use to turn into long term profits.

4. Ocugen Inc. (NASDAQ: OCGN)

Based in Philadelphia and founded in 2013, Ocugen is a clinical-stage biopharmaceutical company that is focussed on developing treatments for rare eye diseases. 

The main reason it is on our list is because of its potential for dramatic growth. With only around 50 employees and a market cap of just over $2 billion, the company has plenty of headroom, especially considering the company had a dramatically higher valuation a few years ago.

While Ocugen currently produces virtually no revenue, investors are banking on one of its innovative treatments reaching commercialisation, though exactly when this will happen remains to be seen. Ocugen is not a stock for the faint of heart, though, for brave investors with an ambitious eye, it could be a winner. 

5. Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

Neurocrine Biosciences is an American biopharmaceutical company founded in 1992 and based in San Diego, California. The company pioneers treatments for neurological and endocrine-related diseases and disorders.

The company’s main drug, Valbenazine, was approved for use in the US for adults with Tardive Dyskinesia in 2017, and this is the main source of its nearly $800 million yearly revenue. Alongside Valbenazine, Neurocrine is developing treatments at various stages of research for Parkinson’s disease, Tourette syndrome, and congenital adrenal hyperplasia.

The fact that Neurocrine has the inherent value of a profitable treatment combined with numerous potentially lucrative clinical-stage treatments has resulted in the company being on this list. We feel it strikes a nice blend of an $8 billion value stock with plenty of growth potential, as its work with a partner to treat endometriosis and uterine fibroids demonstrates. 

Where to buy the best biotech shares

Generally, the best place to find shares is through a reliable stockbroker with low fees. These are online services that allow you to easily control your entire investment portfolio from a single, user-friendly interface.

Min. Deposit
$ 10
User Score
Up to $240 bonus!
Deposit with ACA, Wire, Pay with my bank
Invest for dividends and get payout on stocks on Ex-Dividend day
Start Trading
Payment Methods:
Bank Transfer, Wire Transfer
Full Regulations:
Investoo Ltd is compensated if you access certain of the products or services offered by eToro USA LLC and/or eToro USA Securities Inc., as applicable. This compensation incentivizes Investoo Ltd to describe those products and services in favorable terms. Any testimonials contained in this communication may not be representative of the experience of other eToro customers and such testimonials are not guarantees of future performance or success.
Min. Deposit
$ 100
User Score
Trade out-of-hours on over 70+ US stocks
Get exposure to a wide range of popular UK, US and international stocks
Enjoy flexible access to more than 17,000 global markets, with reliable execution
Start Trading
Payment Methods:
Bank Transfer, Credit Card, Debit Card, PayPal
Full Regulations:
ASIC, FCA, FINMA, is a licensed bank (IG Bank in Switzerland)
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Min. Deposit
$ 0
User Score
$0 commission and $0 Options contract fees
Upgraded research with advanced charts
Smart Menus for faster trades
Start Trading
Payment Methods:
Full Regulations:

What is a biotech stock?

A biotech stock is a publicly-traded company that harnesses biological technology. This can include cellular and biomolecular processes with the main aim of creating technologies that enhance quality of life. A simple example of biotechnology that has been used for generations is the fermentation process for certain kinds of cheese. 

Are biotech shares a good investment?

Biotech stocks are high-risk, high-reward investments. Many of them are in the process of developing drugs that could eventually solve major illnesses and address multi-billion dollar markets. 

However, one misstep can have dramatic consequences. For example, if a US-based biotech company receives approval or rejection on one batch of trial data from the U.S. Food and Drug Administration, it can send a stock soaring or plummeting in a matter of minutes. 

The important thing you need to look for in biotech shares is catalyst moments. Before investing, make sure you are aware of the key dates around which a company’s success or failure will be revealed. 

While there can never be true certainty that a biotech stock will be successful, knowing the major milestones can help you anticipate market movements ahead of time. For the latest news on the biotech sector, click on one of our news links below. 

Latest biotech news

Biogen Inc. (NASDAQ:BIIB) gained more than 48% on Wednesday’s stock premarket. The stock was among the top trends on popular social trading platforms. There were definite reasons. On Tuesday, company news indicated that Biogen and Japanese Eisai had achieved success in Alzheimer’s…
Shares of Biogen Inc (NASDAQ: BIIB) shot up 40% on Wednesday after the biotech firm said its experimental Alzheimer’s drug showed promising results in a Phase III trial. Why is it a big news for Biogen? The Cambridge-headquartered multinational makes “Lecanemab” in collaboration with the Japan-based Eisai Co Ltd…
Moderna Inc (NASDAQ: MRNA) has taken a big hit over the past seven weeks, which, as per an Oppenheimer analyst, is a fantastic opportunity for the long-term investors. Reasons to own the Moderna stock At a price-to-earnings multiple of just over four, the biotech firm is quite attractive in…
AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He’s a Managing Director at Wells Fargo. AbbVie stock has upside to $200 Bansal recommends that you…
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now back to near its year-to-date high but a Morgan Stanley analyst says the stock is not done pleasing its investors yet. Regeneron stock has another 20% upside On Friday, Matthew Harrison upgraded the biotech name to “overweight” and announced a price…
Historically, September tends to be the worst month for the benchmark S&P 500 index. Still, the following two mega-cap names, according to experts, are worth owning here. Chevron Corporation (NYSE: CVX) Chevron is already up more than 30% versus the start of 2022 but Kevin Simpson (Capital Wealth Planning)…

Sources & references
Risk disclaimer

Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >

Charlie Hancox
Financial Writer
Alongside his passion for trading, Charlie has represented Great Britain and won national championships as a water polo player, and as a budding film director, has… read more.
Jayson Derrick
Senior Editor of News
Jayson lives in Montreal with his wife and daughter, loves watching hockey, and is on a lifelong quest to perfect the art of Texas style BBQ. read more.